Therapeutic Variables in Cataract Surgery
Information source: Innovative Medical
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cataract Surgery
Intervention: Gatifloxacin (Drug); Ketorolac LS (Drug); Pred Forte (Drug); Moxifloxacin (Drug); Nepafenac (Drug); EconoPred Plus (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Innovative Medical Official(s) and/or principal investigator(s):
William Trattler, MD, Principal Investigator, Affiliation: The Center For Excellence in Eye Care
Summary
The purpose of this study is to compare patient outcomes in following cataract surgery in
patients randomized to one of two surgical kits.
Clinical Details
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males or females scheduled to undergo cataract surgery
- Patients can be receiving monofocal IOLs only
- Likely to complete all study visits and able to provide informed consent
- Visual potential of 20/25 or better
Exclusion Criteria:
- Known contraindications to any study medication or ingredients
- Active ocular diseases or uncontrolled systemic disease
- Active ocular allergies
Locations and Contacts
The Center for Excellence in Eye Care, Miami, Florida 33176, United States
Additional Information
Last updated: August 17, 2007
|
